Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I

Conclusion A variety of assessment methods beyond palpable spleen length that are easily accessible in the community setting may be useful in evaluating the clinical benefit of ruxolitinib over time in patients with MF. Teaser Ruxolitinib provided clinical benefit for patients with myelofibrosis in clinical trials. However, assessing benefit in community settings remains challenging. This exploratory analysis evaluated results from the phase 3 COMFORT-I trial using practical measures (N=286). Spleen length alone was insufficient for identifying all patients receiving clinical benefit, emphasizing the importance of using multiple myelofibrosis assessment methods in the community setting.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research